Publications
Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Calvert M, Kishishita A, Barpanda A, Zhu J, Maheshwari A, Chen WS, Alshalalfa M, Winters A, Hua JT, Liu T, Davicioni E, Wiita AP, Stohr BA, Siddiqui J, Huang B, Small EJ, Shokat KM, Nelson PS, Quigley DA, Wasmuth EV, Gilbert LA, Feng FY. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nature genetics. 2025. PMID: 41193657
Julia Ye MD, PhD, Nadine Goldhammer PhD, Poonam Vohra MD, Shruti Warhadpande MS, George C. de Castro MD, Cristian K. Maldonado Rodas BS, Mark M. Moasser MD, Kirithiga Ramalingam MD, MAS, Shoko E. Abe MD, Michael Alvarado MD, Cheryl Ewing MD, Karen M. Goodwin DO, FACS, Rita A. Mukhtar MD, Jasmine M. Wong MD, Laura J. Esserman MD, MBA, Ronald Balassanian MD, Jennifer M. Rosenbluth MD, PhD. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ Cancer cytopathology. 2025. PMID:
DeBoer RJ, Uwamahoro P, Ndoli DA, Rugengamanzi E, Mulindabigwi A, Bigirimana JB, Musafiri T, Slater SE, Van Loon K, Sudore RL, Anderson WG, Sanders JJ, Cubaka VK. Adaptation of a serious illness communication training intervention for the Rwandan context. Journal of pain and symptom management. 2025. PMID: 41135916
Schram AM, Naqash AR, Haura EB, Riess JW, Ulahannan SV, Ou SI, Munster PN, Cheng ML, Gustafson WC, Bitman B, Friedman R, Penn R, Kar S, Seshadri V, Wang Z, Tao L, Yang YC, Singh M, Burris HA, Meyerowitz JG. The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 41056387
Johanna Balas, Lauren Bowling, Nonna Shakhnazaryan, Rahul Raj Aggarwal, Hala Borno, Julian C. Hong, Franklin W. Huang, Barry Tong, Daniel H. Kwon. Evaluating an artificial intelligence (AI) communication platform for racial biases in information quality about prostate cancer (PCa) germline testing. JCO oncology practice. 2025. PMID:
Christopher N. Johns, Hala T. Borno, Samuel L. Washington, Wesley Robinson, Miriam Perales, Rahul R. Aggarwal, Rohit Bose, Jonathan Chou, Ivan de Kouchkovsky, Arpita Desai, Kelly N. Fitzgerald, Terence W. Friedlander, Vadim S. Koshkin, Elizabeth Pan, Eric J. Small, Noah S. Younger, Xiaolin Zhu, Franklin W. Huang, Daniel H. Kwon. Development of a Culturally Tailored Educational Tool to Increase Somatic Testing Participation Among Black Men With Metastatic Prostate Cancer. JCO Oncology Advances. 2025. PMID:
Uwamahoro P, Girukubonye I, Bigirimana JB, Shyirambere C, Van Loon K, Sudore RL, Sanders JJ, Cubaka VK, DeBoer RJ. Setting the stage for communication skills training in Rwandan cancer care: a qualitative study of local priorities and key contextual factors. BMC palliative care. 2025. PMID: 41029628
Chari A, van de Donk NWCJ, Dholaria B, Weisel KC, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi KK, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit D, Wäsch R. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025. PMID: 40983036
Smabers LP, Wensink GE, Verissimo CS, Doorn M, Yang T, Voskuilen T, Huismans MA, Valkenburg-van Iersel L, Cirkel GA, Gootjes EC, Verheul HMW, Jeurissen FJ, Bol GM, Nienhuis HH, Braat MNGJA, Cuppen E, Vries RGJ, van der Baan FH, Elias SG, Kranenburg O, Koopman M, Boj SF, Roodhart JML. Patient-derived organoids predict treatment response in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40982295
Chari A, Shenoy S, Kruyswijk S, Hilder B, O'Rourke L, van de Donk NWCJ. Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary. Future oncology (London, England). 2025. PMID: 40951933
Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40689871
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. European urology. 2025. PMID: 40954009
Courau T, Desai A, Wagner A, Combes AJ, Krummel MF. The coming era of nudge drugs for cancer. Cancer cell. 2025. PMID: 40939589
Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan E, Steri V, Porten SP, Koshkin VS, Friedlander TW, Feng FY, Lee JK, Wiita AP, Chu CE, Chou J. Modulating the PPAR? pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nature communications. 2025. PMID: 40931013
Kamgar M, Ko AH. Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40929645
Salami A, Adiele U, Coate G, Diolaiti M, Chen H, Lu J, Ashworth A, Patil M, Fleishman JS, Ramaraju A, Patel A, Patel H, Patel K, Murakami M, Ambudkar SV, Talele TT. Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors. Bioorganic chemistry. 2025. PMID: 40945025
Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40906970
Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson SA, Butte AJ. An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL. Blood advances. 2025. PMID: 40902085
Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40902132
Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies. JCO precision oncology. 2025. PMID: 40893049